Overview of Zafirlukast

Property	Description
Active ingredient	Zafirlukast
Form	Oral Tablet
Pharmacological class	Leukotriene Receptor Antagonist (LTRA)
General purpose	Maintenance therapy for respiratory conditions
Origin	Synthetic

Zafirlukast is a synthetic, non-steroidal medicine classified as a Leukotriene Receptor Antagonist (LTRA), used exclusively in the management of chronic respiratory conditions. This compound requires a prescription and is categorized as an Anti-asthmatic agent intended for long-term control rather than rapid intervention during an acute event. It is designed to modulate the respiratory inflammatory process.

What Type of Medicine is Zafirlukast?

Zafirlukast belongs to the pharmacological class of Leukotriene Receptor Antagonists, which are used for long-term controller therapy for persistent asthma. This designation highlights its function as a foundational treatment. Its action involves the highly selective blockade of the CysLT1 receptor, which is the site where chemical messengers called cysteinyl leukotrienes (LTC4, LTD4, LTE4) exert inflammatory effects. Zafirlukast is distinguished from other LTRAs by its unique chemical structure and specific dosing profile, making its clinical use highly tailored.

Zafirlukast Composition and Dosage Form

The active component in this medication is the single substance Zafirlukast. This substance is provided as a medication via the oral route in the form of a tablet for systemic absorption, meaning it is distributed throughout the body to act on the airways. As a single-ingredient product, the tablets contain only Zafirlukast alongside necessary solid pharmaceutical excipients that give the product its physical form.

General Purpose: Modifying the Inflammatory Response

The fundamental purpose of Zafirlukast is to modify the inflammatory response within the airways. By directly antagonizing the effects of cysteinyl leukotrienes, the medicine is intended to reduce underlying airway hyperresponsiveness and chronic swelling, contributing to the signs and symptoms of asthma. A typical use scenario involves its daily administration to help prevent the onset of symptoms and stabilize lung function. Its general benefit lies in the prophylaxis and chronic treatment of respiratory conditions by maintaining a stable, less-reactive state in the lungs.

What side effects are possible with Zafirlukast?

Possible Side Effects and Safety Information

The official safety profile of Zafirlukast, based on regulatory documentation, defines the spectrum of possible adverse reactions by frequency and physiological system. This classification helps differentiate common, expected events from rare, clinically significant reactions.

Frequency-Classified Adverse Reactions

The most common adverse reactions reported in regulatory sources include headache, nausea, diarrhoea, abdominal pain, and vomiting. Other common effects include myalgia (muscle pain) and asymptomatic elevations in liver transaminase levels.

Less common (ge1/1,000 to <1/100) reactions may involve hypersensitivity reactions, insomnia, arthralgia, pruritus, and general effects like malaise and oedema.

Serious Adverse Reactions and Safety Constraints

A primary focus of the official safety labeling is the hepatobiliary system. Rare to very rare reactions include symptomatic hepatitis, fulminant hepatitis, and hepatic failure, which is potentially life-threatening. The most substantial safety constraint is the contraindication of Zafirlukast in patients with established hepatic impairment, including hepatic cirrhosis, due to reduced clearance.

Rare, but serious, reactions affecting other systems include agranulocytosis (a severe decrease in white blood cells) and features of Churg-Strauss Syndrome (vasculitis), which has been observed primarily when oral corticosteroid doses were being reduced or withdrawn.

Population-Specific Notes

The regulatory data includes specific observations for certain populations. The substantial majority of severe hepatic events, including fulminant hepatitis and hepatic failure, have been reported in females. Additionally, older adults (65 years and older) have a greater reported incidence of infection compared with younger adults. Co-administration with Warfarin is noted in the label as potentially causing a clinically significant increase in bleeding time, necessitating monitoring.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Zafirlukast establishes that, based on clinical experience with excessive doses, no acute toxic effects could be consistently ascribed to the administration of the medicine. However, specific manifestations observed in documented overdose cases include a rash and upset stomach or nausea.

Required Emergency Actions

Immediate medical help must be sought when an overdose is suspected. Government health authorities require that if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened, emergency services must be called immediately. Otherwise, contact with a poison control helpline is recommended to obtain expert guidance.

Official Management and Monitoring

There is no specific antidote documented for Zafirlukast overdose. The regulatory guidance for healthcare professionals dictates that management should involve employing the usual supportive measures and instituting symptomatic therapy. This procedural approach also requires clinical monitoring and steps to remove unabsorbed material from the gastrointestinal tract, which may include the consideration of gastric lavage or activated charcoal in certain situations. No population-specific overdose severity notes are explicitly documented in the official labeling.

Therapeutic Uses of Zafirlukast

What Zafirlukast Treats: Main Uses and Benefits

Zafirlukast is generally used as a dedicated controller medication for the long-term management of persistent respiratory conditions, and it is applied in a prophylactic role rather than an acute rescue function. It is commonly used to help prevent asthma symptoms and is not for sudden attacks. Its utility supports stabilizing airway function and contributing to easing the overall symptom load associated with chronic inflammation.

The medicine is commonly used for managing conditions characterized by episodic or fluctuating manifestations, particularly persistent asthma, the prevention of breathing difficulties related to exercise, and supportive relief in allergic rhinitis and aspirin-associated asthma.

Therapeutic Focus and Benefit

This medicine is primarily applied to help address symptom clusters of persistent asthma, including frequent wheezing, chest tightness, and shortness of breath that may interfere with daily functioning. It provides sustained support that is intended to help reduce the frequency and severity of asthma attacks and is relevant for easing disruptive nighttime awakenings caused by symptoms. Zafirlukast may also assist with maintaining functional stability and may be part of symptomatic management when exercise-related symptoms create noticeable physiological strain. It may help reduce the need for short-acting rescue medication.

Quick Fact: Relief for Nighttime Symptoms

Zafirlukast is considered relevant for easing disruptive nighttime awakenings and symptoms upon waking in the morning, contributing to improved comfort during symptomatic periods.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Zafirlukast?

Zafirlukast eligibility is strictly defined by regulatory documents, focusing on patient age, organ function, and specific physiological states.

Contraindications and Prohibited Use

Zafirlukast is contraindicated in patients with a known hypersensitivity to the drug or any of its components, and in those with hepatic impairment, including hepatic cirrhosis. The medication must not be used for the immediate relief of an acute asthma attack; it is reserved for chronic maintenance therapy.

Age and Special Population Restrictions

Population	Eligibility Status (Regulatory Wording)
Children under 5 years	Safety and efficacy not established (Use Not Established)
Adults and Children ge 5 years	Approved Population
Geriatric Patients (ge 65 years)	Reduced clearance results in higher systemic exposure (Conditional Use)

Reproductive and Organ Status

Zafirlukast is excreted into human breast milk, leading to the official recommendation to discontinue nursing or discontinue the drug. Its safety in human pregnancy is not established. Use is permitted in patients with renal impairment, as no dosage adjustment is required.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Zafirlukast

Interaction Scope	Detail
Medicinal product categories with documented interactions	Anticoagulants; Macrolide antibiotics; Azole antifungals; Analgesics; Xanthine derivatives.
Specific interacting medicines (if explicitly listed)	Warfarin, Erythromycin, Aspirin (Acetylsalicylic acid), Theophylline, Fluconazole.
Mechanistic basis of interactions (only if stated in label)	CYP2C9 isoenzyme inhibition by Zafirlukast (affecting Warfarin); Reduced bioavailability of Zafirlukast (by Erythromycin and Food).
Timing-based interaction rules (if applicable)	Must be administered at least 1 hour before or 2 hours after meals to prevent reduction in Zafirlukast bioavailability.
Population-specific interaction notes (if applicable)	Elderly Patients (65 years and older) exhibit reduced clearance resulting in an approximate doubling of Zafirlukast systemic exposure. Hepatic impairment leads to increased exposure and is a formal contraindication.
Interaction-related restrictions	Formally contraindicated in patients with hepatic impairment or hepatic cirrhosis due to the resulting risk of increased Zafirlukast exposure.

Interaction Classifications (High-Level)

Classification	Detail
Interaction severity classification (as defined in official documents)	Contraindicated (Hepatic Impairment); Clinically significant (Warfarin, requiring monitoring); Exposure-altering (Erythromycin, Aspirin, Theophylline, Food).
Regulatory basis (EMA / FDA / etc.)	Information derived from FDA Prescribing Information and Summary of Product Characteristics (SmPC).
Interaction-context constraints (as defined in official documents)	Must be taken in a fasted state relative to meals; Use is prohibited in the context of any degree of liver impairment.

Resulting Interaction Structure

Official Interaction Statements:

Co-administration with Warfarin results in Zafirlukast inhibiting the CYP2C9 isoenzyme, which increases the mean Prothrombin Time (PT).
Erythromycin decreases the mean plasma concentration of Zafirlukast by approximately 40% due to reduced bioavailability.
Aspirin (Acetylsalicylic acid) increases Zafirlukast mean plasma concentrations by approximately 45%.
Taking the product with food reduces Zafirlukast mean bioavailability by approximately 40%.
The drug's use is formally contraindicated in patients with hepatic impairment or hepatic cirrhosis due to documented reduced clearance leading to increased systemic exposure.

Connection to the overall interaction profile (2–4 sentences):

The regulatory documents define the product's interaction structure primarily through documented pharmacokinetic modifications affecting both Zafirlukast and co-administered medicinal products, notably those metabolized by the CYP2C9 pathway. This structure incorporates specific timing rules based on documented food-based bioavailability reduction and imposes a clear contraindication related to patient physiology (hepatic impairment) due to severe exposure alteration. The profile documents alterations in drug exposure when co-administered with Warfarin, Erythromycin, Aspirin, and Theophylline.

Mechanism of Action

Selective Blockade of the CysLT1 Receptor

Zafirlukast acts as a Leukotriene Receptor Antagonist that targets and modulates a defined inflammatory signaling pathway in the airways. The drug operates as a selective competitive antagonist at the Cysteinyl Leukotriene Receptor Type 1 ( CysLT1). This molecular action prevents the inflammatory mediators cysteinyl leukotrienes ( LTD4, LTC4, LTE4) from engaging their primary receptor. The blockade interrupts the G-protein coupled signaling cascade that would otherwise activate inflammatory and smooth muscle responses in the bronchi.

️ Modulating Airway Muscle Tone and Reactivity

By suppressing the LTD4-mediated signal, the mechanism directly inhibits the stimulus for bronchial smooth muscle contraction. This sustained reduction in inflammatory signaling maintains a more relaxed airway caliber, reducing the overall degree of airway hyperresponsiveness ( AHR). This effect relies on chronic pathway modulation, reflecting that its action is primarily sustained and preventative of pathway activation.

Attenuation of Airway Swelling

The CysLT1 receptor blockade also limits the vasoactive effects of leukotrienes, reducing the increase in local vascular permeability within the airway mucosa. This action contributes to limiting chronic airway edema and mucus secretion, which are driven by sustained inflammatory mediator activity. The overall physiological outcome involves the sustained modulation of muscle constriction and chronic tissue thickening.

Dosage and Administration Information

Zafirlukast is administered exclusively via the oral route as a tablet and is intended for chronic, long-term administration as a controller medication.

Official Administration Principles

The core use protocol for Zafirlukast mandates a strict twice-daily (b.i.d.) dosing schedule to maintain a steady systemic concentration. This frequency applies across all approved age groups.

A critical constraint on administration is the requirement to take the medicine on an empty stomach. Standard instructions specify that the tablet must be taken at least one hour before a meal or two hours after a meal. This timing is essential because food significantly reduces the absorption of the active compound.

Dosage and Procedural Guidance

The standard dose for adults and adolescents 12 years of age and older is 20 mg twice daily. For children aged 5 through 11 years, the labeled dose is 10 mg twice daily. The medicine is not approved for use in children younger than five years old.

Since this is a daily maintenance treatment, guidance addresses missed timing. If a dose is missed, the instruction is to skip the missed dose and continue with the next scheduled dose; the dose should not be doubled to compensate for the skipped interval. The medicine must be continued regularly, even during periods of stability.

Recent Clinical Evidence

Research evidence / Overview of studies for Zafirlukast

The clinical evidence for Zafirlukast is grounded in Randomized Controlled Trials (RCTs) and systematic reviews primarily investigating its use for the long-term management of persistent asthma. These studies evaluated outcomes related to systemic or functional imbalance when the medicine was compared against a placebo.

Core Efficacy and Prevention Studies

Research examined objective measurements of lung function, such as the forced expiratory volume (FEV1), and patient-reported outcomes describing the frequency of wheezing, shortness of breath, and disruptive nighttime awakenings. Studies also monitored the frequency of rescue inhaler use. Furthermore, research has examined Zafirlukast in the context of preventing breathing difficulties related to exercise, primarily through controlled Challenge Studies, which evaluated changes in the airways following specific physical activity.

Long-Term Data and Research Limitations

The primary evidence for Zafirlukast comes from trials with limited follow-up durations, typically lasting around 13 weeks. While subsequent open-label studies extended observation up to two years, long-term effects are not fully established.

Findings indicate that in certain long-term studies, researchers observed patterns suggesting that initial responses may not be maintained consistently. Research has been conducted in Adults, Adolescents (age 12 and older), and Children (age 5 to 11). However, the safety and efficacy data remain insufficient for the pediatric population younger than 5 years of age. Overall, the evidence provides context but not individual predictions, and research does not determine how an individual will experience the observed group patterns.

Key Studies & References Zafirlukast (Oral Route) Drug Information

Frequently Asked Questions (FAQ)

Common questions about Zafirlukast (FAQ)

Q: How quickly do people usually start to feel a difference after starting Zafirlukast?

A: Zafirlukast is designed for long-term control rather than rapid relief. Official information indicates that the active drug compound reaches its highest concentration in the blood about three hours after taking a dose. However, the medicine works by providing a sustained, preventative effect, meaning its full intended effect is dependent upon continued chronic administration over several weeks.

Q: Why does my doctor call Zafirlukast a leukotriene modifier?

A: Zafirlukast is classified as a Leukotriene Receptor Antagonist (LTRA). 'Leukotriene modifier' is a common term for this drug class. This means it works by blocking the effects of specific inflammatory chemicals called leukotrienes, which are produced by the body’s immune system and contribute to asthma symptoms.

Q: Are there any common mental or mood side effects with Zafirlukast?

A: Official documents describe the possibility of experiencing new or worsening mental and mood changes while taking this medication. The reported effects include agitation, anxiety, depression, confusion, sleep problems, vivid dreams, or hallucinations. The product information also notes the potential for suicidal thoughts or actions.

Q: Is Zafirlukast similar to Singulair (Montelukast)?

A: According to regulatory sources, Zafirlukast is classified as a Leukotriene Receptor Antagonist (LTRA), which is the same pharmaceutical class as Montelukast (Singulair). This means both are types of non-steroidal medications used for the long-term, chronic management of persistent asthma symptoms.

Q: Does Zafirlukast interact with common pain relievers like ibuprofen?

A: Regulatory documents note an interaction specifically with Aspirin (acetylsalicylic acid), which can result in increased Zafirlukast levels in the body. Detailed interaction studies for other common pain relievers, such as ibuprofen, are not explicitly detailed in the same section of the official product label.

Q: What happens if a dose of Zafirlukast is missed?

A: Official patient guidance describes that the missed dose should be skipped, and the patient should resume with the next scheduled dose as normal. The regulatory guidance strictly specifies that the dose should not be doubled to compensate for the skipped interval.

Q: Are there any reported drug interactions between Zafirlukast and blood thinners?

A: Official regulatory documents detail a known and significant interaction with the anticoagulant medication Warfarin (a blood thinner), which can increase the effects of Warfarin. Other types of newer blood thinners are not explicitly detailed in the same sections of the official product label.

Q: What is the average time it takes to see the maximum effect of Zafirlukast?

A: Zafirlukast is a chronic maintenance therapy and is not a quick-relief medicine. Studies reviewing the effectiveness of the drug often have observation periods lasting around 13 weeks. This reflects the period needed for the chronic effect to stabilize and be monitored in long-term control.

Q: Is it normal for Zafirlukast to be prescribed for seasonal allergies?

A: According to the official FDA label, Zafirlukast is approved and indicated for the chronic treatment and prevention of asthma. Uses for other conditions, such as seasonal allergies, are not listed as an approved indication in the official regulatory documentation.

Q: Is Zafirlukast available as a chewable or liquid form?

A: Zafirlukast is supplied exclusively in the form of an oral tablet for the approved use. Official regulatory documentation does not list a chewable tablet, liquid, or any other formulation besides the oral tablet.

Q: Is Zafirlukast used for breathing problems other than asthma?

A: The official indication for Zafirlukast is limited to the prevention and chronic treatment of asthma symptoms. The regulatory label does not include other specific breathing problems or respiratory conditions as an approved use for the medication.

Q: Can Zafirlukast be stopped suddenly?

A: The official guidance advises against stopping the medication suddenly on one's own. Its role as a chronic controller means its continuous use is generally required, and any changes must be discussed with a healthcare provider.

Q: Is Zafirlukast considered an 'add-on' therapy for asthma?

A: Regulatory documents classify Zafirlukast as a maintenance therapy for persistent asthma symptoms. This means it is used to control the condition over the long term and can be used in combination with other treatments as part of a comprehensive management plan.

Q: How does Zafirlukast affect the body's response to allergens?

A: Official studies on Zafirlukast describe that pretreatment with the drug attenuated (reduced the severity of) the early and late-phase reactions caused by the inhalation of various antigens (allergens) in people with asthma. This effect is part of its overall anti-inflammatory action in the airways.

Q: Are there any known side effects that involve the skin?

A: The official safety profile notes possible side effects involving the skin. These include pruritus (itching) and the occurrence of a rash. These are generally categorized as less common or rare reactions.

Q: Is Zafirlukast used to treat cough?

A: Zafirlukast is officially indicated for the prevention and chronic treatment of asthma. While cough is often a symptom of asthma, the official label does not list cough as a specific condition or symptom the drug is used to treat.

Q: Is Zafirlukast a controlled substance?

A: Zafirlukast is classified as a non-controlled substance under the Controlled Substances Act (CSA). This means the medication does not require special regulatory scheduling or restrictions typically applied to drugs with a high risk of abuse or dependence.

Q: Does taking Zafirlukast mean I can stop using my other asthma medications?

A: Regulatory guidance specifies that Zafirlukast is typically part of a comprehensive treatment plan, and patients should not stop taking or reduce the dose of other prescribed asthma medications unless they have been instructed to do so by a healthcare provider.

Q: Are there non-asthma conditions that Zafirlukast is sometimes used for?

A: Zafirlukast is indicated exclusively for the prevention and chronic treatment of asthma. Regulatory information warns against using the medication for conditions other than those for which it was formally prescribed.

Q: How is the long-term safety of Zafirlukast described in official documents?

A: The official long-term safety profile highlights the potential for rare but serious issues, particularly concerning the liver, including severe hepatic failure. Rare cases of Churg-Strauss syndrome have also been reported. Additionally, reduced drug clearance is noted in the older adult population (65 years and older).

Q: Is it known if Zafirlukast affects the immune system?

A: Zafirlukast is part of the Leukotriene Receptor Antagonist drug class. These medicines work by blocking the actions of leukotrienes, which are specific inflammatory chemicals produced by the body’s immune system that contribute to airway swelling and tightening in asthma.

How should Zafirlukast be stored and disposed of?

Storage and Disposal Information for Zafirlukast

Zafirlukast tablets require storage at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), to maintain product stability. The medicine must be actively protected from light and excess moisture; the official labeling advises against storing it in the bathroom.

Handling and Protection

The tablets must be kept in the original container, which should be tightly closed. It is mandatory to keep Zafirlukast out of the sight and reach of children.

Disposal Requirements

Expired or unused Zafirlukast must be discarded according to local, state, and federal regulations. Do not dispose of this medication by flushing it down a toilet or sink.

Zafirlukast